Skip to main content
OpenTrials
Completed

NCT Number: NCT01804023

Biomarkers of Protocol Compliance and Product Adherence

The purpose of this study is to compare tests of vaginal insertion of applicators(visual inspection of returned applicators (VIRA), inspection of returned applicators under ultraviolet (UV) light, and DNA/protein markers) to determine which, if any, warrant use in a clinical trial of a new vaginal microbicide. The study will also determine whether indicators of semen can be detected on applicators and the degree to which they correlate with reported intercourse, and the correlation between vaginal bacteria detected by a vaginal swab and those detected from the applicator. In addition, the study will determine whether several factors that may be encountered in a clinical trial are likely to affect detection of these markers, including storage for 30 days vs. 7 days, wiping applicators after use, the presence of gel, and inter- and intra-woman variability. The study will also assess safety.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV Prevention

Age range

18 year–50 year

Sex eligibility

Female

Study type

Observational

Primary location

Clinical Research Center, Eastern Virginia Medical School

Norfolk, Virginia, 23507, United States

About this study

Screening tests will be performed to detect exclusion criteria. After confirming the absence of point-of-care exclusion criteria, four applicators (#1 to 4, "sham" applicators) will be handled by the participant, but not inserted into the vagina and the gel will be expelled into a waste container. Four applicators (#5 to 8) will be inserted into the participant's vagina, one at a time, by the investigator, removed, and then the gel will be expelled into a waste container. Two applicators (#9 and 10) will be inserted into the participant's vagina, one at a time, and gel will be expelled into the participant's vagina. Finally, two applicators (#11 and 12) will be inserted into the participant's vagina, one at a time, by the investigator, removed and then the gel expelled into a waste container. Applicators #11 and 12 will then be wiped clean with a paper towel. Thus, each participant will provide a total of 12 applicators, half of which will be processed within one week of her visit and half of which will be processed in approximately one month of her visit. Three readers blinded to the status of the applicators (sham, inserted with or without gel expulsion) will determine, by VIRA and UV light assessment, whether or not the applicators were inserted vaginally. Additional laboratory personnel, who will also be blinded to the status of the applicators, will process the applicators for DNA and protein markers of product adherence and protocol compliance.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 to 50 years old
  • In good health, as evidenced by history
  • No use of vaginal medications in the past 7 days
  • At least 3 days from the end of their last menses
  • Willing and able to comply with study procedures

Exclusion criteria

  • Surgery or biopsy of the vagina or cervix within 30 days
  • Have a history of a total hysterectomy (removal of the uterus and cervix)
  • Pregnancy
  • Positive buccal HIV test
  • Other conditions that, in the opinion of the investigator, would constitute contraindications to participation in the study or would compromise the ability to comply with study protocols, such as any major chronic illness or a major psychiatric disorder (e.g., schizophrenia)
  • Current participation in any other drug or device study, or any study which, in the opinion of the investigator, would jeopardize interpretation of results of this study

Treatment and study plan

HEC placebo gel applicators

Other

Participants will handle, but not insert, 4 applicators containing HEC placebo gel.

Participants will vaginally insert and removed 8 applicators containing HEC placebo gel. Gel will be expelled in to the vagina from only 2 applicators.

Primary outcomes

  1. Sensitivity, specificity, PPV, and NPV of the following indicator of vaginal insertion: VIRA

    Time frame: 7 days after insertion of vaginal applicators

  2. Number of applicators on which Y chromosome-associated genes can be detected and degree of correlation between detection and the number of days since last penile/vaginal intercourse

    Time frame: 7 days after insertion of vaginal applicators

  3. Degree of correlation of vaginal species obtained from vaginal applicators and vaginal species obtained from vaginal swabs

    Time frame: 7 days after insertion of vaginal applicators

  4. Sensitivity, specificity, PPV, and NPV of the following indicator of vaginal insertion: VIRA

    Time frame: 30 days after insertion of vaginal applicators

  5. Sensitivity, specificity, PPV, and NPV of the following indicator of vaginal insertion: UV Light Inspection

    Time frame: 7 days after insertion of vaginal applicators

  6. Sensitivity, specificity, PPV, and NPV of the following indicator of vaginal insertion: UV Light Inspection

    Time frame: 30 days after insertion of vaginal applicators

  7. Sensitivity, specificity, PPV, and NPV of the following indicator of vaginal insertion: DNA sequences of vaginal bacteria

    Time frame: 7 days after insertion of vaginal applicators

  8. Sensitivity, specificity, PPV, and NPV of the following indicator of vaginal insertion: DNA sequences of vaginal bacteria

    Time frame: 30 days after insertion of vaginal applicators

  9. Sensitivity, specificity, PPV, and NPV of the following indicator of vaginal insertion: Immunohistochemical tests for protein markers

    Time frame: 7 days after insertion of vaginal applicators

  10. Sensitivity, specificity, PPV, and NPV of the following indicator of vaginal insertion: Immunohistochemical tests for protein markers

    Time frame: 30 days after insertion of vaginal applicators

  11. Number of applicators on which Y chromosome-associated genes can be detected and degree of correlation between detection and the number of days since last penile/vaginal intercourse

    Time frame: 30 days after insertion of vaginal applicators

  12. Degree of correlation of vaginal species obtained from vaginal applicators and vaginal species obtained from vaginal swabs

    Time frame: 30 days after insertion of vaginal applicators

Secondary outcomes

  1. Difference in detection of these markers when applicators are processed within one week versus approximately 30 days after the participant's visit

    Time frame: 30 days after insertion of vaginal applicators

  2. Difference in the sensitivity, specificity, NPV and PPV of detection of these markers when applicators are wiped off after removal from the vagina

    Time frame: 7 days after insertion of vaginal applicators

  3. Difference in detection of these markers when gel is present, either from a current applicator insertion and gel expulsion or from previous and current applicator insertion and gel expulsion

    Time frame: 7 days after insertion of vaginal applicators

  4. Difference in the sensitivity, specificity, NPV and PPV of detection of these markers when applicators are wiped off after removal from the vagina

    Time frame: 30 days after insertion of vaginal applicators

  5. Difference in detection of these markers when gel is present, either from a current applicator insertion and gel expulsion or from previous and current applicator insertion and gel expulsion

    Time frame: 30 days after insertion of vaginal applicators

Sponsors and collaborators

Lead sponsor

CONRAD

Other

Registry information

Official study title

Comparison of Objective Biomarkers of Protocol Compliance and Product Adherence With Classic Markers of Compliance and Adherence

Important dates

Study start
2013
Primary completion
2013
Study completion
2013
First posted
Mar 5, 2013
Registry last updated
Oct 30, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.